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Between 1990 and 2001, 265 pts were treated at the University 
of Colorado in prospective HDC trials for stage II/III breast can- 
cer involving 4-9, >10 + nodes, or inflammatory disease (IBC). Pts 
received standard chemotherapy, followed by HDC (cyclophos- 
phamide 5, 625, cisplatin 165, and BCNU 600 mg/m 2) with 
AHPCT, radiotherapy, and tamo~fen x 5 yrs if estrogen/proges- 
terone receptor (ER/PR) +. Outcome There were 13 (4.9%) 
HDC-related deaths, with no age effect (p=0.3). 2 pts developed 
acute myelogenous leukemia t >5 yrs post-HDC. At median F/U 
of survivors of 7 (1-11) yrs, the relapse-free (RFS) and overall sur- 
vival (OS) rates are 66.7% (95% CI, 61-72%) and 70.2% (65- 
76%), respectively. Median RFS and OS times have not been 
reached. Actuarial RFS/OS rates are 68%/72% at 5 yrs, and 
65%/67% at 10 yrs. No differences in RFS (p=0.3) or OS (p=0.3) 
were detected among the 3 groups (table). Median time to relapse 
was 14 months. Of the 74 relapses, 47 (63.5%) occurred in the 
first 2 yrs after HDC (1st yr: 31, 2nd yr: 16), 22 (29.7%) in yrs 2- 
5, and 5 (6.7%) after the 5th yr. Prognos6c analyses 1) No effect 
of age on relapse was detected (p=0.6). 2) A multivariable analysis 
of a subset of 175 pts treated through 7/97 resulted in the t~)llow- 
ing model: Score = [tumor size (can) x 0.l 5] + [nodal ratio x 3.05] - 
[ER/PR x 1.1] (Nodal ratio = # + nodes /# dissected nodes), 
(ER/PR -0 if -, =1 if +). Scores >2.41 and <2.41 confer >50% and 
<20% relapse risks, respectively (p<0.00001). The score was exter- 
nally validated (Duke). 3) At current minimum F/U >5 yrs, the 
score remains significant in our first subset(p-0.0001). It was 
prospectively validated in 77 pts treated since 7/97 (median FlU 3 
yrs) (p=0.003). 4) HER2 was another independent predictor 
(p=0.0003). 5) A final model combines the score and HER2 
(p<0.0000I): Low risk (low score + HER2 -) (N-91): 87% DFS; 
Intermediate risk (low score + HER2+) (N=5 I): 59% DFS; High 
risk (high score, any HER2) (N=51): 49% DFS. Conclusions: 1) 
Our encouraging long-term results, with few relapses een after 5 
yrs, indicate the need for mature FlU of the randomized trials. 2) 
hnportant prognostic factors can be identified that may help inter- 
pret the randomized trials, as well as select pts for testing of novel 
HDC-based strategies. 
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Despite progress in chemotherapy, a large number of patients 
suffering from ST always die from cancer evolution. Conversely 
ASCT has shown its potential  to eradicate mal ig-nant 
hemopathies by immune control. On these bases we aimed to 
establish if ASCT may represent a potential treatment in ST with 
acceptable toxicity in a multicenter program. 46 consecutive 
patients (age: 43(18 60)) with refractory ST (RCC:16; Breast:10; 
Ovarian:6; Melanoma:6; others:8) (Prog disease (PD)/stable dis- 
ease (SD):32/14) were included from 96/12 to 01/11 in this study 
to be grafted from a HLA identical sibling in 8 centers. Standard 
ASCT with myeloablative conditioning regimen (MAR) and BMT 
was used in the 6 initial patients. Then MAR was switched to 
reduced intensity regimen (RIR) is combining fludara-bin (180 
rag/m2), ATG (1 to 4 days) and reduced Busulfan (8 mg/kg) in the 
40 following pa-tients and followed by allo graft (BMT/PBSCT: 
16/14). In this setting of advanced iseases, we found that RfR 
offered low TRiM (5% (95% CI: 0-12%)). An antimmoral effect 
could be docmnented (Objective response (PR+CR) (OR) - 18% 
(95% CI:6%-30%)) (RCC:2; breast:2; ovarian:3; melanoma:l) at a 
median of 90 days (30-190) post transplant and was associated 
with a higher 12 month smwival (OR (N=8) vs. no OR (N=38) 75 
% vs. 12 % p=0.001). Patients with SD prior to transplant pre- 
sented a higher OR rate (50 % vs. 3 %; p=0.0006): this was the 
only factor statistically predicting OR (odd ratio = 11.4 (95% CI: 
1.4-92); p=0.02) in a Cox analysis model. Disease status at trans- 
plant and cGVHD significativc]y influenced ly survival in a land- 
mark analysis tarting on day 100 (SD/PD: 56% vs. 21% (p=0.03); 
cGVHD/No: q3% vs. 6% (p=0.02)). These 2 factors remain inde- 
pendent in a nmltivariate analysis (odd ratio (95% CI): cGVHD: 
3.5 (1.4-8.5), p=0.007; Stable disease: 3.4(I.3-8.9), p=0.02). In this 
perspective, PBSCT seems to be the best choice offering a higher 
rate of cGVItD (BMT vs. PSCT: 14% vs. 76 %; p=0.0006) with 
out an increased mortality. Results show that such a RIR followed 
by allogeneic PBSCT represents a valid option to investigate allo 
geneic immunotherapy in various subsets of solid tumors and 
deserves fl~rther studies 
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PURPOSE: To evaluate the correlation f the early lymphocyte 
recovery, with outcome in pts with high-risk primary breast cancer 
(HRPBC) and metastatic breast cancer (MBC) receiving HDC. 
PAT IENTS AND METHODS:  We analyzed the prognostic 
effect of the absolute lymphocyte count (ALC) on day +15 post- 
transplant in pts enrolled between 1990-200l in prospective trials 
of HDC (cyclophosphamide/cisplatin/BCNU) at the University of 
Colorado. RESULTS: 478 pts (265 HRPBC, 213 MBC) were 
evaluated at median follow up of 6 (1-11) years. The disease-free 
survival (DFS) and overall survival (OS) rates were 66% and 70%, 
respectively, in the HRPBC group, and 22% and 37%, respective- 
ly, in MBC pts. D+15 ALC was higher in I IRPBC than in MBC 
pts (930 vs. 500/mm 3, p=0.01). D+15 ALC did not correlate with 
age (p=0.8) or with the graft total nucleated cell dose (p=0.7). A 
very weak correlation was detected between D+15 ALC and the 
CD34+ cell dose (r2=0.06, p=0.005). D+15 ALC correlated with 
DFS (p-0.007) and OS (p-0.03) in MBC pts (table). In contrast, it 
was not associated with DFS (p=0.5) or OS (p=0.8) in HRPBC. 
The prognostic ffect of ALC in MBC was observed in pts receiv- 
ing peripheral-blood progenitor cells (N=137) (p=0.04), but not 
bone marrow (N-43) (p=0.8). Likewise, an effect from D+15 ALC 
,was seen in MBC pts receiving an unselected (N-134, p=0.04), but 
not a CD34-selected graft (N=79, p=0.8). In multivariate analyses, 
a high D+15 ALC was an independent protective factor in MBC, 
both for DFS, with a hazard ratio (HR) of 0.65 (p=0.02), and for 
OS (HR:0.7, p=0.04). These analyses included other variables also 
associated with outcome in univariate analyses of our MBC group: 
disease stares at transplant, # metastatic sites, radiotherapy deliv- 
ery, specific organ involved, primary a~llary nodal status, primary 
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